​
​

Immunome Stock (NASDAQ:IMNM)

ForecastRevenueOwnershipFinancialsChart
Immunome by TradingView

Previous Close

$9.39

52W Range

$6.93 - $30.96

50D Avg

$13.02

200D Avg

$16.16

Market Cap

$582.35M

Avg Vol (3M)

$690.10K

Beta

1.82

Div Yield

-

IMNM Company Profile

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

55

IPO Date

Oct 02, 2020

Website

IMNM Performance

IMNM Financial Summary

Dec 23Dec 22Dec 21
Revenue$14.02M--
Operating Income$-109.53M$-36.90M$-25.20M
Net Income$-106.81M$-37.51M$-24.47M
EBITDA$-108.80M$-36.27M$-24.70M
Basic EPS$-5.38$-3.09$-2.12
Diluted EPS$-5.38$-3.09$-2.12

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

TickerCompany
ANABAnaptysBio, Inc.
CYTCyteir Therapeutics, Inc.
IKNAIkena Oncology, Inc.
MLYSMineralys Therapeutics, Inc.
AVTEAerovate Therapeutics, Inc.
ACRVAcrivon Therapeutics, Inc. Common Stock
CSBRChampions Oncology, Inc.
GANXGain Therapeutics, Inc.
ANTXAN2 Therapeutics, Inc.
LTRNLantern Pharma Inc.
MNOVMediciNova, Inc.
TFFPTFF Pharmaceuticals, Inc.
INABIN8bio, Inc.
RZLTRezolute, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
ADAGAdagene Inc.
MOLNMolecular Partners AG
LIFEaTyr Pharma, Inc.
CELCCelcuity Inc.